TP53 and colitis: Taken together, our study demonstrated that CsA could lower the activity of the PPP rate-limiting enzyme G6PD and inhibit a large number of ROS produced through intracellular PPP metabolism (specifically by down-regulating NADPH/NADP +) by activating P53 protein, thus reducing the formation of NETs and alleviating colitis.